Michael Marash, Ph.D., Founder & CEO, P-Cure
P-Cure was founded to expand the availability of proton therapy to benefit more patients, and to enhance the benefits that proton therapy brings to treating and curing cancer.
I didn’t start out to “shift the paradigm” for treatment planning and treatment delivery. My intention was to design proton therapy around the patient in a more natural and anatomically correct solution.
In addition to new clinical benefits, I wanted to make proton therapy more available to patients. Access today is very limited: less than 1 percent of the patients that can benefit from proton therapy have access to this advanced form of treatment.
Why aren’t more cancer patients benefiting from the superior benefits of proton therapy?
The capital cost of developing a proton center has been the limiting factor in making proton therapy available. Today, there appears to be more options for reducing start-up costs, mainly by building a one-room center. But the lower cost is illusionary: a multi-room center of 3 or 4 rooms may cost between $140-$180 million and a one room center may cost between $40-$50 million. Comparing the cost per treatment vault, the proportional cost is approximately the same for a large proton center as it is for a one-room center.
P-Cure has shifted the paradigm by reducing the costs of a one room expandable center to approximately half the price of any other system currently available. The savings are even greater for a two-room center. Also, we are supplying systems that are adaptive therapy ready.
When we say “See P-Cure First,” we mean that we have the solution for the most cost-effective center, with the shortest time for ROI, and a more compassionate, effective form of treatment planning and delivery.
I believe P-Cure is part of a series of paradigm-shifting developments. We are committed to “primum non nocere”, from the Hippocratic Oath, “first, do no harm.”
Physicians have looked for ways to use radiation to treat cancer since the discovery of x-rays over a century ago. Advances in technology and a better understanding of its effects on the body have made radiation therapy an important part of cancer treatment.
P-Cure offers a patient-centric focus to proton therapy that further enhances the precision of the “Beam of Hope,” while concurrently making the possibility of proton therapy more accessible through significantly lower equipment and construction costs.
The P-Cure solution is part of the continuum to advance what’s best for the patient. We’re honored to hear what William Hartsell, MD, Radiation Oncologist, and Medical Director at Northwestern Medicine Proton Center says of the P-Cure solution:
“The technology is an important addition to our proton offering. We expect that imaging lung cancer patients in the upright position will allow us to more precisely target the tumor when we treat it with proton therapy.”
Dr. Michael Marash is the founder and the CEO of the company. During the past 10 years, Dr. Marash led the company from the concept to the product commercialization. Under his leadership the company entered in collaboration with the major medical equipment providers such as Philips Medical Systems and others. His relationship in the field enabled to set partnership with strategically important healthcare providers and radiation oncology developers, significantly expending the company pipeline. Before P-Cure, Dr. Marash managed technology at Vecta Ltd, a biotech company, succeeding to bring several gastrointestinal and oncology products to the clinical development phases. Earlier, Dr. Marash was involved in the development of robotic image-guided diagnostic devices in several Hi-Tech companies. His professional experience is backed up with groundbreaking scientific accomplishments published in the most prestigious peer review journals. He's served in the Medical Troops in Israeli Defense Force and holds the MBA and the Ph.D. degrees from the Ben Gurion University and the Weizmann Institute of Science, respectively.
Mr. Wyant is the Managing Director of Everett Partners, Ltd., the venture investing arm of the Kanfer family and the Managing Director of Fir Hill, LLC, a venture services business. He also serves as a Director of Great Lakes Pharmaceuticals in Beachwood, Ohio. Mr. Wyant is also the Chairman of the Targetech Innovation Center, a technology incubator in Netanya, Israel. In addition he also serves as a member of the Ohio Venture Capital Task Force. Mr. Wyant is an experienced entrepreneur and commercialization expert. He has been involved with technology commercialization for over 25 years. His experience ranges from the protection of intellectual property, licensing, and new venture formation, to prototype demonstration and the sale of new products and services. Mr. Wyant has been a manager or advisor for companies in a variety of industries including advanced imaging, health services, alternative energy, and food technology. His work experience also includes over six years as a manager of the licensing and venturing arm of the University of Chicago where he was responsible for building and managing a portfolio of intellectual property for the University of Chicago and Argonne National Laboratory. Prior to his technology commercialization work, Mr. Wyant held various sales and marketing positions at a multi-national industrial gas company. Mr. Wyant holds BS degrees in chemical and biomedical engineering from Northwestern University and an MBA in marketing and finance from the University of Chicago.
Mrs. Nir served as a Managing Director and Head of Life Sciences at Giza Venture Capital. She also served as the Chief Operating Officer, as well as Development and Operations Manager at Biosense Webster, Inc. (Israel), Johnson & Johnson, leading a team of 150 people in the development and manufacture of state of the art medical electromagnetic navigation systems. Previously, Mrs. Nir served as Vice President of Research and Development and Vice President of Marketing for Medical Division at General Electric Company. She served as the Vice President of Engineering and Research and Development at General Electric Medical Systems, Israel, leading 100 researches and developing Nuclear Medicine systems. Mrs. Nir also served as a Vice President of Marketing, Sales & Customer Support at ELGEMS (GE & Elscint) and Product Manager at Elscint, Medical Imaging. She serves as chairperson and Director of several private and public medical device companies. Mrs. Nir is a board director of the Israeli High Tech Association (IATI). She holds a B.Sc. degree in Computer Science from Technion-Israel's Institute of Technology and a degree Business Administration from the University of Haifa.
Mr. Halpert is a finance management and control expert with many years of experience in diverse industries such as: Electronics, Cellular, Chemistry. Mr. Halpert designed, operated, managed and controlled complex systems mainly in the telecom market. Mr. Halpert implemented new methodologies in various operational fields. He was the finance manager of the first Israeli cellular phone company - Motorola, CFO of Wind Turbine, Tadiran Industries and more.
Dr. Tochner is the Clinical Director of Proton Therapy Project at University of Pennsylvania. Opening in 2010, The Roberts Proton Therapy Center has integrated the most advanced technological developments. Dr. Tochner was one of the leading specialists who determined the clinical and technological needs of the center. In addition, Dr. Tochner is a Clinical Director of University of Pennsylvania’s Department of Radiation Oncology and currently serves as Chief of Neuro-Oncology and Pediatric Radiation Oncology Department. Prior to this, Dr. Tochner held several senior positions at the NCI’s Radiation Oncology Branch and at Hadassah University Hospital in Jerusalem, where he served as the Head of the Oncology Department. Dr. Tochner joined P-CURE when the enterprise was first launched.
Prof. Kooy is the Director of Physics at the Francis H. Burr Proton Therapy Center at the Massachusetts General Hospital in Boston, and an Associate Professor of Radiation Therapy at HarvardMedicalSchool. During the last 15 years, Prof. Kooy has led the medical physics development in proton therapy at the center and has become a well recognized scientific figure in the field. His recent book “Proton and Charged Particle Radiotherapy”, written with Tomas F. DeLaney, MD, is a reference textbook for radiotherapy specialists. The F. H. Burr Proton Therapy Center continues the clinical program that commenced at the Harvard Cyclotron Lab in the late ‘60’s where Robert Wilson conceptualized the clinical use of protons in 1947.
Dr. Pfeffer is the Chief of the Radiation Oncology Department at the Chaim Sheba Medical Center in Israel. Like Dr. Tochner, he joined P-Cure right at the beginning and since then he has been acting as a leading clinical consultant. Dr. Pfeffer is a world-renowned specialist in the field of radiation therapy and a talented scientist. His knowledge, experience and scientific creativity allow the company to formulate the best clinically valuable solutions for both oncologists and patients. Dr. Pfeffer completed his medical studies at the University College Hospital Medical School in London and a combined Clinical and Research Fellowship at the Harvard Joint Center for Radiotherapy. Dr. Pfeffer participates in clinical studies with the European Organization for Research and Treatment of Cancer Radiotherapy Group.
Stephen Jacobs has played a critical role in the clinical development of proton therapy. Experienced in governmental affairs, marketing and public relations, he consulted to the first proton center at Loma Linda University Medical Center and the technology transfer from Department of Energy Fermi National Accelerator Lab. For over 30 years, he has led the campaign to fund proton therapy research and development through advocacy, Congressional appropriations and governmental support. Mr. Jacobs is a founding Board member of the National Association of Proton Therapy. He is former Assistant Secretary of the US Department of Energy, and a strategic planner under three US presidents. He has consulted to proton therapy vendors, start-ups, major corporations and non-profits, and prepared business/marketing plans for developing proton centers. He holds a B.S. degree from the University of Maryland, and an M.A. from The American University